MedTrace Logo

Oral Administration of DCI to Women With PCOS

NCT00497653 · Status: TERMINATED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 13

Last updated 2011-11-16

No results posted yet for this study

Summary

To determine if oral DCI administration to women with PCOS increases the total DCI content in urine and blood, and, if so, if that change is accompanied by i) an increase in DCI-IPG release in blood (as determined by bioactivity) during an oral glucose challenge and ii) an increase in whole-body insulin sensitivity.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

DCI

D-chiro-inositol 1200mg twicely daily for 6 weeks

DRUG

Placebo

Placebo, twice daily for 6 weeks

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • Virginia Commonwealth University

    lead OTHER

Principal Investigators

  • John E. Nestler, MD · Virginia Commonwealth University

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-02-28
Primary Completion
2007-07-31
Completion
2009-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00497653 on ClinicalTrials.gov